{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:10:05Z","timestamp":1780765805780,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug discovery is a complex, time-intensive, and costly process, often requiring more than a decade and substantial financial investment to bring a single therapeutic to market. Drug repurposing, the systematic identification of new indications for existing approved drugs, offers a cost-effective and expedited alternative to traditional pipelines, with the potential to address unmet clinical needs. In this study, we present a comparative analysis of drug\u2013target interaction data from three extensively curated resources: ChEMBL, BindingDB, and GtoPdb, evaluating their release histories, curation methodologies, and coverage of approved and investigational compounds and targets. To facilitate therapeutic interpretation, we manually classified ChEMBL targets into 12 high-level biological families and mapped 817 clinically approved drug indications into 28 broader therapeutic groups. This structured framework enabled a systematic profiling of physicochemical properties among approved drugs across therapeutic categories. Our analyses revealed associations between physicochemical characteristics and therapeutic groups, providing practical guidance for indication-specific compound prioritization and refining the repurposing studies. We also examined cross-indication drug approvals to identify areas with high repurposing potential. Finally, we implemented a pathway-based computational pipeline to predict repositioning opportunities for FDA-approved drugs across 10 major cancer types, demonstrating its adaptability to other disease contexts. Overall, this work consolidates drug-target data and computational repurposing into a data-driven framework that advances drug discovery and translational applications.<\/jats:p>","DOI":"10.1093\/bib\/bbaf625","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:57:50Z","timestamp":1763992670000},"source":"Crossref","is-referenced-by-count":6,"title":["Data-driven strategies for drug repurposing: insights, recommendations, and case studies"],"prefix":"10.1093","volume":"26","author":[{"given":"Susanna","family":"Savander","sequence":"first","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM) , HiLIFE, University of Helsinki, Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurettin Nusret","family":"Curabaz","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM) , HiLIFE, University of Helsinki, Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna Mumtaz","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM) , HiLIFE, University of Helsinki, Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asifullah","family":"Khan","sequence":"additional","affiliation":[{"name":"Pakistan Institute of Engineering & Applied Sciences (PIEAS) , Islamabad ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Saeed","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM) , HiLIFE, University of Helsinki, Helsinki,","place":["Finland"]},{"name":"King Abdullah International Medical Research Center (KAIMRC) , King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-9862","authenticated-orcid":false,"given":"Ziaurrehman","family":"Tanoli","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM) , HiLIFE, University of Helsinki, Helsinki,","place":["Finland"]},{"name":"BioICAWtech , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2025112408574703200_ref1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"2025112408574703200_ref2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025112408574703200_ref3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s43586-021-00084-5","article-title":"DNA-encoded chemical libraries","volume":"2","author":"Satz","year":"2022","journal-title":"Nature Reviews Methods Primers"},{"key":"2025112408574703200_ref4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-2624-5_7","article-title":"Proteome integral solubility alteration (PISA) for high-throughput ligand target deconvolution with increased statistical significance and reduced sample amount","volume":"2554","author":"Gaetani","year":"2023","journal-title":"Methods Mol Biol"},{"key":"2025112408574703200_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae496","article-title":"Attention-based approach to predict drug\u2013target interactions across seven target superfamilies","volume":"40","author":"Schulman","year":"2024","journal-title":"Bioinformatics"},{"key":"2025112408574703200_ref6","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1021\/acsomega.1c05203","article-title":"TransDTI: transformer-based language models for estimating DTIs and building a drug recommendation workflow","volume":"7","author":"Kalakoti","year":"2022","journal-title":"ACS Omega"},{"key":"2025112408574703200_ref7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","article-title":"Evolutionary-scale prediction of atomic-level protein structure with a language model","volume":"379","author":"Lin","year":"2023","journal-title":"Science"},{"key":"2025112408574703200_ref8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"2025112408574703200_ref9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17460441.2024.2430955","article-title":"Validation guidelines for drug-target prediction methods","volume":"20","author":"Tanoli","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"2025112408574703200_ref10","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref11","doi-asserted-by":"publisher","first-page":"D1633","DOI":"10.1093\/nar\/gkae1075","article-title":"BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data","volume":"53","author":"Liu","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref12","doi-asserted-by":"publisher","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS guide to PHARMACOLOGY in 2024","volume":"52","author":"Harding","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/bay083","article-title":"Drug target commons 2.0: a community platform for systematic analysis of drug-target interaction profiles","volume":"2018","author":"Tanoli","year":"2018","journal-title":"Database (Oxford)"},{"key":"2025112408574703200_ref14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"2025112408574703200_ref15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/bib\/bbaa003","article-title":"Exploration of databases and methods supporting drug repurposing: a comprehensive survey","volume":"22","author":"Tanoli","year":"2021","journal-title":"Brief Bioinform"},{"key":"2025112408574703200_ref16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41573-025-01164-x","article-title":"Computational drug repurposing: approaches, evaluation of in silico resources and case studies","volume":"24","author":"Tanoli","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2025112408574703200_ref17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/90761","article-title":"ADMET\u2014turning chemicals into drugs","volume":"19","author":"Hodgson","year":"2001","journal-title":"Nat Biotechnol"},{"key":"2025112408574703200_ref18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM198012183032516","article-title":"Reversal of baldness in patient receiving minoxidil for hypertension","volume":"303","author":"Zappacosta","year":"1980","journal-title":"N Engl J Med"},{"key":"2025112408574703200_ref19","first-page":"28","article-title":"Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec)","volume":"97","author":"Joensuu","year":"2002","journal-title":"Med Klin (Munich)"},{"key":"2025112408574703200_ref20","doi-asserted-by":"publisher","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"PubChem 2025 update","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1758-2946-5-3","article-title":"UniChem: a unified chemical structure cross-referencing and identifier tracking system","volume":"5","author":"Chambers","year":"2013","journal-title":"J Chem"},{"key":"2025112408574703200_ref22","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"Oosterom","year":"2001","journal-title":"Lancet"},{"key":"2025112408574703200_ref24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/shem.2003.50037","article-title":"Imatinib: a targeted clinical drug development","volume":"40","author":"Capdeville","year":"2003","journal-title":"Semin Hematol"},{"key":"2025112408574703200_ref25","doi-asserted-by":"publisher","first-page":"217441","DOI":"10.1016\/j.canlet.2025.217441","article-title":"Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer","volume":"611","author":"Hindes","year":"2025","journal-title":"Cancer Lett"},{"key":"2025112408574703200_ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7497\/j.issn.2095-3941.2014.01.001","article-title":"Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies","volume":"11","author":"Phan","year":"2014","journal-title":"Cancer Biol Med"},{"key":"2025112408574703200_ref27","doi-asserted-by":"publisher","first-page":"1279159","DOI":"10.3389\/fmicb.2023.1279159","article-title":"A cooperativity between virus and bacteria during respiratory infections","volume":"14","author":"Lalbiaktluangi","year":"2023","journal-title":"Front Microbiol"},{"key":"2025112408574703200_ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antibiotics10030326","article-title":"Antimicrobial resistance in common respiratory pathogens of chronic bronchiectasis patients","volume":"10","author":"Inchingolo","year":"2021","journal-title":"A Literature Review, Antibiotics (Basel)"},{"key":"2025112408574703200_ref29","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.1038\/s41467-025-62407-4","article-title":"A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance","volume":"16","author":"He","year":"2025","journal-title":"Nat Commun"},{"key":"2025112408574703200_ref30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"2025112408574703200_ref31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood.V21.6.699.699","article-title":"The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute Leukemia: a model for evaluation of other potentially useful therapy","volume":"21","author":"Freireich","year":"1963","journal-title":"Blood"},{"key":"2025112408574703200_ref32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/35101056","article-title":"Pharmacogenetics and cancer therapy","volume":"1","author":"Relling","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"2025112408574703200_ref33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/pme-2020-0183","article-title":"Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection","volume":"18","author":"Vohra","year":"2021","journal-title":"Perinat Med"},{"key":"2025112408574703200_ref34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41577-020-00421-x","article-title":"After 62 years of regulating immunity, dexamethasone meets COVID-19","volume":"20","author":"Cain","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025112408574703200_ref35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s43440-023-00501-4","article-title":"Polypharmacology: promises and new drugs in 2022","volume":"75","author":"Ryszkiewicz","year":"2023","journal-title":"Pharmacol Rep"},{"key":"2025112408574703200_ref36","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref37","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2025112408574703200_ref38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barabasi","year":"2011","journal-title":"Nat Rev Genet"},{"key":"2025112408574703200_ref39","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat Rev Chem"},{"key":"2025112408574703200_ref40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"2025112408574703200_ref41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41540-022-00221-0","article-title":"Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects","volume":"8","author":"Paci","year":"2022","journal-title":"NPJ Syst Biol Appl"},{"key":"2025112408574703200_ref42","doi-asserted-by":"publisher","first-page":"10331","DOI":"10.1038\/ncomms10331","article-title":"Network-based in silico drug efficacy screening","volume":"7","author":"Guney","year":"2016","journal-title":"Nat Commun"},{"key":"2025112408574703200_ref43","doi-asserted-by":"publisher","first-page":"1352803","DOI":"10.3389\/fmed.2024.1352803","article-title":"Drug repurposing for rare: progress and opportunities for the rare disease community","volume":"11","author":"Jonker","year":"2024","journal-title":"Front Med (Lausanne)"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/26\/6\/bbaf625\/65490400\/bbaf625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/26\/6\/bbaf625\/65490400\/bbaf625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:57:52Z","timestamp":1763992672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaf625\/8341157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaf625","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11,1]]},"article-number":"bbaf625"}}